Form 10-Q REGENERON PHARMACEUTICAL For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Regeneron Pharma (REGN) PT Lowered to $1,185 at RBC Capital
May 3, 2024 6:46 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,185.00 (from $1,189.00) while maintaining a Outperform rating.
The analyst comments "Overall, a reasonably solid quarter, with Eylea HD looking good, Eylea 2mg missing probably to a... More
